Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 8

Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease

Authors Panos RJ

Received 3 January 2013

Accepted for publication 11 February 2013

Published 30 April 2013 Volume 2013:8 Pages 221—230


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Ralph J Panos1,2

1Pulmonary, Critical Care, and Sleep Medicine Division, Cincinnati Veterans Affairs Medical Center, 2Pulmonary, Critical Care, and Sleep Medicine Division, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Background: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality and its treatment is critical to improve quality of life, reduce symptoms, and diminish the frequency of COPD exacerbations. Due to the harmful environmental effects of pressurized metered-dose inhalers (pMDIs) containing chlorofluorocarbons (CFCs), newer systems for delivering respiratory medications have been developed.
Methods: A search of the literature in the PubMed database was undertaken using the keywords “COPD,” “albuterol,” “ipratropium bromide,” and “Respimat® Soft Mist Inhaler™”; pertinent references within the identified citations were included. The environmental effect of CFC-pMDIs, the invention of the Respimat® Soft Mist Inhaler™ (SMI) (Boehringer Ingelheim, Ingelheim, Germany), and its use to deliver the combination of albuterol and ipratropium bromide for the treatment of COPD were reviewed.
Results: The adverse environmental effects of CFC-pMDIs stimulated the invention of novel delivery systems including the Respimat SMI. This review presents its development, internal mechanism, and use to deliver the combination of albuterol and ipratropium bromide.
Conclusion: CFC-pMDIs contributed to the depletion of the ozone layer and the surge in disorders caused by harmful ultraviolet B radiation. The banning of CFCs spurred the development of novel delivery systems for respiratory medications. The Respimat SMI is an innovative device that produces a vapor of inhalable droplets with reduced velocity and prolonged aerosol duration that enhance deposition within the lower airway and is associated with improved patient satisfaction. Clinical trials have demonstrated that the Respimat SMI can achieve effects equivalent to pMDIs but with lower medication doses. The long-term safety and efficacy remain to be determined. The Respimat SMI delivery device is a novel, efficient, and well-received system for the delivery of aerosolized albuterol and ipratropium bromide to patients with COPD; however, the presence of longer-acting, less frequently dosed respiratory medications provide patients and providers with other therapeutic options.

Keywords: Respimat® Soft Mist Inhaler™, COPD, pressurized metered-dose inhaler, chlorofluorocarbons

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Other article by this author:

Health care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPD

Joseph Seaman, Anthony C Leonard, Ralph J Panos

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:89-97

Published Date: 31 March 2010

Readers of this article also read:

Screening of feature genes in distinguishing different types of breast cancer using support vector machine

Wang Q, Liu XD

OncoTargets and Therapy 2015, 8:2311-2317

Published Date: 27 August 2015

Amperometric urea biosensors based on sulfonated graphene/polyaniline nanocomposite

Das G, Yoon HH

International Journal of Nanomedicine 2015, 10:55-66

Published Date: 25 August 2015

A stewardship intervention program for safe medication management and use of antidiabetic drugs

Zhao RY, He XW, Shan YM, Zhu LL, Zhou Q

Clinical Interventions in Aging 2015, 10:1201-1212

Published Date: 23 July 2015

Results of endocapsular phacofracture debulking of hard cataracts

Davison JA

Clinical Ophthalmology 2015, 9:1233-1238

Published Date: 10 July 2015

The efficacy and mechanism of apoptosis induction by hypericin-mediated sonodynamic therapy in THP-1 macrophages

Li XS, Gao L, Zheng LB, Kou JY, Zhu X, Jiang YQ, Zhong ZY, Dan JH, Xu HB, Yang Y, Li H, Shi S, Cao WW, Zhao YJ, Tian Y, Yang LM

International Journal of Nanomedicine 2015, 10:821-838

Published Date: 22 January 2015

Challenge models to assess new therapies in chronic obstructive pulmonary disease

van der Merwe R, Molfino NA

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:597-605

Published Date: 13 September 2012

Erratum - Intracellular heavy metal nanoparticle storage

Iannitti T, Capone S, Gatti A, et al

International Journal of Nanomedicine 2011, 6:239-240

Published Date: 26 January 2011